DCision-making in tumors governs T cell anti-tumor immunity
| Autor: | Francesca Alfei, Ping-Chih Ho, Wan-Lin Lo |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Cancer Research Stromal cell T cell Biology Lymphocyte Activation Antibodies Article 03 medical and health sciences 0302 clinical medicine Immune system Genetics medicine Tumor Microenvironment Humans Molecular Biology Cancer immunology Tumor microenvironment Dendritic cell Immune checkpoint 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Cancer cell Cancer research Immunotherapy |
| Zdroj: | Oncogene |
| ISSN: | 1476-5594 |
| Popis: | The exploitation of T cell-based immunotherapies and immune checkpoint blockade for cancer treatment has dramatically shifted oncological treatment paradigms and broadened the horizons of cancer immunology. Dendritic cells have emerged as the critical tailors of T cell immune responses, which initiate and coordinate anti-tumor immunity. Importantly, genetic alterations in cancer cells, cytokines and chemokines produced by cancer and stromal cells, and the process of tumor microenvironmental regulation can compromise dendritic cell–T cell cross-talk, thereby disrupting anti-tumor T cell responses. This review summarizes how T cell activation is controlled by dendritic cells and how the tumor microenvironment alters dendritic cell properties in the context of the anti-tumor immune cycle. Furthermore, we will highlight therapeutic options for tailoring dendritic cell-mediated decision-making in T cells for cancer treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink